Compass Pathways has announced six‑month results from its second phase 3 trial of COMP360, its synthetic formulation of ...

Years ago, LSD was seen as the evil stepchild of drugs. Today, research indicates LSD may treat anxiety and depression, and ...

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the 26-week results (Part B) from its second ongoing ...

Heat domes are becoming more frequent. Learn how to spot heat exhaustion and stay hydrated to keep yourself safe.

Katie Couric, 69, was hospitalized overnight after she lost her recent memories on June 27, forgetting the year and who is ...

New 26-week data from the phase 3 COMP006 study validate the long-term durability, safety, and remission potential of a 2-dose COMP360 psilocybin regimen for highly chronic, treatment-resistant ...

Medical conditions - full list. Notifiable conditions are medical issues that could potentially compromise your ability to ...

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of ...

USA: Findings from the nonrandomized STUN-AF study suggest that, among patients undergoing concomitant pulsed-field ablation ...